Science Without Boundaries: Metastatic NSCLC Highlights from WCLC 2026

The International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) brought the global thoracic oncology community to Seoul, Republic of Korea, from September 12–15. This year's theme, "Science Without Boundaries: Uniting the World Against Thoracic Cancer," was truly fitting for a meeting where research from Asia, Europe, and the Americas shaped the conversation around approaches to treating metastatic/advanced non-small cell lung cancer (NSCLC). Longer survival follow-up, new first-line options for rare mutations, and a growing focus on healthcare

EGFR in 2026: What’s New and What’s Next

LUNGevity offers a variety of virtual support groups called ‘meetups’ where survivors and caregivers impacted by lung cancer connect with others who understand the patient experience. Once a month, we invite an expert to share information on a topic related to life with lung cancer, engage with attendees, and answer questions in real time. Visit the LUNGevity Calendar to see upcoming events like this one. In September, we were joined by Dr. Benjamin Levy, MD, thoracic medical oncologist and clinical director of medical oncology for the Johns Hopkins Sidney Kimmel Cancer Center at Sibley

Science Without Boundaries: Small Cell Lung Cancer Highlights from WCLC 2026

The 2026 World Conference on Lung Cancer (WCLC) brought the global thoracic oncology community to Seoul, South Korea from September 12–15. This year's theme, "Science Without Boundaries: Uniting the World Against Thoracic Cancer," was particularly fitting for small cell lung cancer (SCLC). Data from two exciting phase 3 clinical trials were discussed as part of the conference’s plenary sessions and we saw scientific progress across every part of the patient journey. Here are the conference highlights, organized by limited-stage (LS) and extensive-stage (ES) disease. Limited-Stage SCLC Can we

Small Cell SMASHERS Fireside Chat with Dr. Misty Shields

In October, we hosted a special Small Cell SMASHERS Fireside Chat with our two hosts, Misty Shields, MD, PhD, Indiana University School of Medicine, and Ann Steagall, LUNGevity’s SVP of Patient Services and Health Care Delivery. During this session, Dr. Shields and Ann talked through the latest treatment options for small cell lung cancer. The Small Cell SMASHERS Fireside Chat is a monthly virtual series highlighting the latest discoveries and breakthroughs for small cell lung cancer.

Podcast: Managing the Side Effects of Small Cell Lung Cancer Treatment

What side effects should you expect from small cell lung cancer treatment—and when should you call your care team? In this episode, small cell lung cancer (SCLC) survivor Vickie Rose shares her journey through chemotherapy, radiation, immunotherapy, and tarlatamab, and the practical, hard-won strategies she uses to keep eating, stay active, and feel well on treatment. Clinical pharmacist Mya Tran, PharmD, BCOP, Indiana University (IU) Health Simon Comprehensive Cancer Center, joins Vickie and hosts Ann Steagall and Misty Shields, MD, to explain how side effects differ across chemotherapy

Podcast: What Do I Need to Know About Nutrition During Cancer Treatment?

Should you avoid sugar when you are living with lung cancer? Or should you eat anything you want? Are supplements something you need to consider? In this episode, non-small cell lung cancer survivor Diane Beall shares how she approaches nutrition, from mindful eating to her go-to snacks for low-appetite days. Thoracic oncologist Jared Weiss, MD, University of North Carolina, joins Diane and hosts Ann Steagall and Misty Shields, MD, to discuss sugar and supplements, explain why he often recommends liberalizing a cancer patient's diet, and share practical, drug-specific nutrition tips—from

Small Cell SMASHERS Fireside Chat with Dr. Jacob Sands

In August, we were joined by Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology and Assistant Professor of Medicine at Harvard Medical School. Dr. Sands discussed The Importance of HOPE: Highlighting Recent Advancements in SCLC. Moderated by Misty Shields, MD, PhD, Indiana University School of Medicine, and LUNGevity’s Upal Basu Roy, PhD, MPH, Executive Director of Research, this monthly virtual series highlights the latest discoveries and breakthroughs for SCLC.

Podcast: Managing the Emotional Rollercoaster of Lung Cancer

Living with lung cancer can take more than just a physical toll—it comes with a myriad of feelings, like anxiety, fear, and grief. In this episode, non-small cell lung cancer (NSCLC) survivor and advocate Nora Taylor shares her journey through diagnosis, clinical trials, and targeted therapy, along with the rollercoaster of emotions that go with it. Licensed clinical social worker Ashley Griffin joins Nora as well as hosts Ann Steagall and Misty Shields, MD, to explain why anxiety and depression are such a common and often unspoken part of the cancer experience. She offers practical, everyday

New Treatment Approved for ROS1-positive NSCLC

On July 22, 2026, the US Food and Drug Administration (FDA) announced the approval of zidesamtinib (Jideytro™) to treat patients with locally-advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). This approval is for patients who have been previously treated with ROS1-targeted tyrosine kinase inhibitors (TKIs). Mutations in the ROS1 gene are responsible for approximately 2% of NSCLCs. And they are more common in younger patients (median age is 50 years), females, and never-smokers. Zidesamtinib is a type of targeted therapy that is given as a daily pill. It is a tyrosine

Getting to the Bone of the Matter: Bone-Modifying Agents

LUNGevity offers a variety of virtual support groups called ‘meetups’ where survivors and caregivers impacted by lung cancer connect with others who understand the patient experience. Once a month, we invite an expert to share information on a topic related to life with lung cancer, engage with attendees, and answer questions in real time. Visit the LUNGevity Calendar to see upcoming events like this one. In June, we welcomed Duc Huynh, PharmD, BCOP, MD Anderson Cancer Center, to talk about bone-modifying agents. Topics covered in this 20-minute video include: How do bones naturally change